Cingulate (CING) Corporate presentation summary

Market opportunity and unmet needs

• ADHD stimulant market exceeds $10 billion with over 100 million prescriptions annually, dominated by extended-release products and significant dissatisfaction among patients, representing a large opportunity for new entrants.

• Approximately 25% of prescriptions reflect dissatisfaction, equating to 20 million prescriptions as a potential target for improved therapies.

• Current ADHD treatments often require booster doses, have suboptimal onset and duration, and are associated with rebound/crash effects.

Product innovation and clinical differentiation

• Precision Timed Release (PTR) platform enables true once-daily, multi-dose tablets with fast onset and extended efficacy, aiming to eliminate the need for booster doses.

• CTX-1301 demonstrated entire active-day efficacy, rapid onset (<30 min), and minimized crash/rebound in clinical studies.

• Clinical data show CTX-1301 provides a 91% improvement in active-day performance over placebo and a higher effect size than leading competitors.

• CTX-1301 exhibited significantly lower adverse events compared to Focalin XR, with a 28.6% reduction in treatment-emergent adverse events.

Commercialization and go-to-market strategy

• Commercial launch of CTX-1301 is planned for 1H 2027, with preparations covering all major pharma functions and partnerships with industry leaders for commercialization.

• Launch strategy includes a 110-120 person sales team, omnichannel marketing, and targeting 54,000 ADHD providers on day one.

• Payer research indicates positive reimbursement prospects, with CTX-1301 rated most valuable among ADHD brands and likely to gain broad coverage.

• Go-to-market execution involves phased market conditioning, access strategy, precision targeting, and post-launch optimization.